Browse > Article

Effect of Cytarabine, Melphalan, and Total Body Irradiation as Conditioning for Autologous Stem Cell Transplantation for Patients with AML in First Remission  

Kang Ki Mun (Department of Therapeutic Radiology, Gyeongsang National University)
Choi Byung Ock (Department of Radiation Oncology, The Catholic University)
Chai Gyu Young (Gyeongsang Institute of Health Sciences)
Kang Young Nam (Department of Radiation Oncology, The Catholic University)
Jang Hong Sek (Department of Radiation Oncology, The Catholic University)
Kim Hee Jae (The Catholic Hematopoietic Stem Cell Transplantation Center)
Min Wo Sung (The Catholic Hematopoietic Stem Cell Transplantation Center)
Kim Chun Choo (The Catholic Hematopoietic Stem Cell Transplantation Center)
Choi Ihl Bohng (The Catholic Hematopoietic Stem Cell Transplantation Center)
Publication Information
Radiation Oncology Journal / v.21, no.3, 2003 , pp. 192-198 More about this Journal
Abstract
Purpose: Current results of autologous stem cell transplantation (SCT) suggest that this procedure may prolong disease free survival In patients with acute myeloid leukemia (AML). Autologous SCT is increasingly used as treatment for AML in first remission. The aim of this study was to evaluate the outcome of autologous SCT for patients with AML in first remission treated by autologous SCT using cytarabine, melphalan and total body irradiation (TBI) as the conditioning regimen. Materials and Methods: Between January 1995 and December 1999, 29 patients with AML in first remission underwent autologous SCT. The median age of patients was 33 years (range, 16 to 47). The conditioning regimen consisted of cytarabine ($3.0\;gm/m^2$ for 3 days), melphalan ($100\;gm/m^2$ for 1 day) and TBI (total 1000 cGy in five fractions over 3 days). Results: The median follow up was 40 months with a range of 3 to 58 months. The 4-year cumulative probability of disease free survival was 69.0%, and median survival was 41.5 months. The 4-year relapse rate was 27.6%. The factor Influencing disease free survival and relapse rate was the French-American-British (FAB) classification ($M_3$ group vs. other groups; p=0.048, p=0.043). One patient died from treatment-related toxicity. Conclusion:: Although the small number of patients does not allow us to draw any firm conclusion, our results were encouraging and suggest that the association of cytarabine, melphalan and TBI as a conditioning regimen for autologous SCT for AML on first remission appears to be safe and effective.
Keywords
AML; Autologous stem cell transplantation; Total body irradiation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998;92:1073-1090   PUBMED
2 Chung SM, Choi IB , Kim IA, et al. Results of total body irradiation in allogeneic bone marrow transplantation for acute non-lymphocytic leukermia. J Korean Soc Ther Radiol 1992;10:247-253
3 Kang KM, Choi IB, Kim IA, et al. Total body irradiation for allogeneicstemcelltransplantationfor patients withacute myleoid leukemia in first remission. Kor J Hematopoietic Stem Cell Transplant 2000;5:223-230
4 Min WS, Cho SG, Chung IJ, et al. Autologous bone marrow transplanatation for acute myeloid leukemia in first remission; purging with hyperthermia and ether lipid in vitro. J KoreanCancer Association 1996;28:670-677
5 DusenberyKE,SteinbuchM,McGlavePB,etal. Autologous bone marrow transplantation in acute myeloid leukemia: the University of Minnesota experience.IntJRadiatOncolBiol Phys 1996;369:335-343
6 Down JD, Tarbell NJ, Thames HD. Syngeneic and allogeneic bone marrow engraftment after total body irradiation: Dependence on total dose, dose rate, and fractionation. Blood 1991;77:661-669   PUBMED
7 Reiffers J, Labopin M, Sanz M, et al. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in completeremission: an EBMTretrospectiveanalysis.Bone Marrow Transplant 2000;25:1115-1119   DOI   ScienceOn
8 RohatinerAZ,BassanR,RaimondiR,et al. High-dosetreatment with autologous bone marrow support as consolidation of firstremissionin youngerpatients withacutemyelogenous leukaemia. Ann Oncol 2000;11:1007-1015   DOI   ScienceOn
9 Ball ED. In vitro purging of bone marrow for autologous marrow transplantation in acute myelogenous leukemia using myeloid-specific monoclonal antibodies. Bone Marrow Transplant 1988;3:387-392   PUBMED
10 Meloni G, De Fabritiis P, Carella AM, et al. Autologous bone marrow transplantation in patients with AML in first complete remission. Results of two different conditioning regimens after the same induction and consolidation therapy. Bone Marrow Transplant 1990;5:29-32   PUBMED
11 Thomas ED. Total body irradiation regimens for marrow grafting. Int J Radiat Oncol Biol Phys 1990;19:1285-1288   DOI   PUBMED   ScienceOn
12 Metayer C,Curtis RE, VoseJ,etal. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case control study. Blood 2003;101:2015-2023   DOI   ScienceOn
13 Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481   DOI   ScienceOn
14 Glasgow GP, Beetham KL, MillWB. Dose rate effects on the survival of normal hematopoietic stem cells of BALB/c mice. Int J Radiat Oncol Biol Phys 1983;9:557-563   DOI   PUBMED   ScienceOn
15 Bonetti F, ZeccaM,PessionA,etal. Totalbody irradiationand melphalanisasafeandeffectiveconditioningregimenfor autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. The Italian Association forPediatric Hematology and Oncology- Bone Marrow Transplantation Group. J Clin Oncol 1999;17: 3729-3735   DOI   PUBMED
16 Kang KM, Choi IB, Choi BO, et al. Fractionated total body irradiation for allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia. Kor J Hematopoietic Stem Cell Transplant 1999;4:269-277
17 Sierra J, Granena A,Garcia J, etal. Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients. Bone Marrow Transplant 1993;12:517-523   PUBMED
18 Meloni G, De Fabritiis P, Papa G, et al. Cryopreserved autologous bone marrow infusion following high dose chemotherapy in patients withacute myeloblasticleukemia in first relapse. Leuk Res 1985;9:407-412   DOI   ScienceOn
19 TomasJF,Gomez-GarciadeSoriaV,PinillaI,etal. Bone marrow autotransplantation in acute myeloblastic leukemia in its firstcompleteremission. The clinical results in 41 patients. Med Clin Barc 1997;108:201-206
20 Ringden O, Labopin M, Tura S, e t a l . A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning forautograftorallograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the EuropeanGroupforBloodandMarrowTransplantation.Br J Haematol 1996;93: 637-645
21 BallED,WilsonJ,PhelpsV,NeudorfS. Autologous bone marrow transplantationforacute myeloid leukemia inremission or first relapse using monoclonal antibody-purged marrow: results of phase IIstudieswith long-term follow-up. Bone Marrow Transplant 2000;25:823-829   DOI   ScienceOn
22 Donato V, Iacari V, Zurlo A, et al. Fractionated total body irradiation in allogeneic bone marrow transplantation in leukemia patients: analysis of prognostic factors and results in 136 patients. Radiother Oncol 1998;48:267-276   DOI   ScienceOn
23 Matsuyama T, Horibe K, Kato K, Kojima SS. Bone marrow transplantation for children with acute myelogenous leukaemia in the first complete remission. Eur J Cancer 2000;36:368-375   DOI   ScienceOn
24 Dusenbery KE, Daniels KA, McClure JS, et al. Randomized comparison of cyclophosphamide-total body irradiation versus busulfan-cyclophosphamide conditioning in autologous bone marrow transplantation for acute myeloid leukemia. Int J Radiat Oncol Biol Phys 1995;31:119-128   DOI   PUBMED   ScienceOn